Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMVT Immunovant	$17.94 +1.4%	$15.86	$12.72 ▼ $34.47	$3.03B	0.63	1.22 million shs	924,629 shs
MLTX MoonLake Immunotherapeutics	$53.57	$44.79	$31.42 ▼ $58.26	$3.43B	1.27	386,366 shs	341,713 shs
PTGX Protagonist Therapeutics	$54.99 -0.4%	$51.29	$32.50 ▼ $60.60	$3.42B	2.26	841,697 shs	680,283 shs
REPL Replimune Group	$2.81 -77.2%	$9.62	$2.68 ▼ $17.00	$950.09M	0.61	1.31 million shs	86.52 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMVT Immunovant	+1.36%	+2.57%	+13.54%	+24.15%	-35.93%
MLTX MoonLake Immunotherapeutics	0.00%	+7.85%	+23.15%	+35.59%	+19.84%
PTGX Protagonist Therapeutics	-0.42%	-0.60%	+3.09%	+19.13%	+52.33%
REPL Replimune Group	-77.19%	-77.34%	-69.69%	-68.25%	-71.44%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IMVT Immunovant	1.5557 of 5 stars	3.4	0.0	0.0	2.8	1.7	0.0
MLTX MoonLake Immunotherapeutics	1.5118 of 5 stars	3.5	1.0	0.0	0.6	2.5	0.0
PTGX Protagonist Therapeutics	1.5247 of 5 stars	2.5	1.0	0.0	3.5	2.5	0.0
REPL Replimune Group	4.7044 of 5 stars	4.4	1.0	4.5	3.2	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMVT Immunovant	2.82	Moderate Buy	$36.30	102.34% Upside
MLTX MoonLake Immunotherapeutics	3.00	Buy	$74.50	39.07% Upside
PTGX Protagonist Therapeutics	3.00	Buy	$66.10	20.20% Upside
REPL Replimune Group	2.70	Moderate Buy	$11.38	304.80% Upside

Current Analyst Ratings Breakdown

Latest REPL, PTGX, MLTX, and IMVT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/22/2025	REPL Replimune Group	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$31.00 ➝ $6.00
7/22/2025	REPL Replimune Group	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$3.00
7/22/2025	REPL Replimune Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$19.00 ➝ $9.00
7/22/2025	REPL Replimune Group	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$3.00
7/22/2025	REPL Replimune Group	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Neutral	$19.00 ➝ $4.00
7/16/2025	REPL Replimune Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$16.00 ➝ $19.00
7/10/2025	IMVT Immunovant	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$18.00
7/3/2025	REPL Replimune Group	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
6/20/2025	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
6/17/2025	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$72.00
6/3/2025	MLTX MoonLake Immunotherapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$67.00

(Data available from 7/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.16 per share	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$7.09 per share	N/A
PTGX Protagonist Therapeutics	$434.43M	7.85	$4.50 per share	12.23	$11.33 per share	4.85
REPL Replimune Group	N/A	N/A	N/A	N/A	$5.40 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMVT Immunovant	-$413.84M	-$2.74	N/A	N/A	N/A	N/A	-80.60%	-71.89%	8/5/2025 (Estimated)
MLTX MoonLake Immunotherapeutics	-$118.94M	-$2.30	N/A	N/A	N/A	N/A	-30.81%	-28.40%	8/6/2025 (Estimated)
PTGX Protagonist Therapeutics	$275.19M	$0.75	73.32	N/A	N/A	27.04%	9.22%	8.31%	8/5/2025 (Estimated)
REPL Replimune Group	-$247.30M	-$3.07	N/A	N/A	N/A	N/A	-57.98%	-45.21%	8/14/2025 (Estimated)

Latest REPL, PTGX, MLTX, and IMVT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q1 2026	REPL Replimune Group	-$0.85	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q1 2025	MLTX MoonLake Immunotherapeutics	-$0.73	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q1 2026	IMVT Immunovant	-$0.69	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	PTGX Protagonist Therapeutics	-$0.53	N/A	N/A	N/A	$8.32 million	N/A
5/29/2025	Q4 2025	IMVT Immunovant	-$0.72	-$0.64	+$0.08	-$0.64	N/A	$0.16 million
5/22/2025	Q4 2025	REPL Replimune Group	-$0.75	-$0.82	-$0.07	-$0.82	N/A	N/A
5/12/2025	Q1 2025	MLTX MoonLake Immunotherapeutics	-$0.76	-$0.63	+$0.13	-$0.63	N/A	N/A
5/6/2025	Q1 2025	PTGX Protagonist Therapeutics	-$0.50	-$0.19	+$0.31	-$0.19	$30.44 million	$28.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMVT Immunovant	N/A	11.16	11.16
MLTX MoonLake Immunotherapeutics	0.18	21.11	21.11
PTGX Protagonist Therapeutics	N/A	17.25	17.26
REPL Replimune Group	0.17	7.95	7.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMVT Immunovant	47.08%
MLTX MoonLake Immunotherapeutics	93.85%
PTGX Protagonist Therapeutics	98.63%
REPL Replimune Group	92.53%

Insider Ownership

Company	Insider Ownership
IMVT Immunovant	1.80%
MLTX MoonLake Immunotherapeutics	12.05%
PTGX Protagonist Therapeutics	4.90%
REPL Replimune Group	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMVT Immunovant	120	171.07 million	167.99 million	Optionable
MLTX MoonLake Immunotherapeutics	2	64.01 million	56.30 million	Optionable
PTGX Protagonist Therapeutics	120	61.98 million	58.95 million	Optionable
REPL Replimune Group	210	77.09 million	70.30 million	Optionable

REPL, PTGX, MLTX, and IMVT Headlines

Recent News About These Companies

Replimune Group (NASDAQ:REPL) Hits New 12-Month Low Following Analyst Downgrade

1 hour ago | americanbankingnews.com

Brokerages Set Replimune Group, Inc. (NASDAQ:REPL) PT at $21.00

2 hours ago | americanbankingnews.com

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

July 22 at 4:45 PM | businesswire.com

Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock

July 22 at 3:01 PM | investors.com

Jefferies Financial Group Has Lowered Expectations for Replimune Group (NASDAQ:REPL) Stock Price

July 22 at 2:57 PM | marketbeat.com

Replimune Group (NASDAQ:REPL) Downgraded to Market Perform Rating by Leerink Partners

July 22 at 2:16 PM | marketbeat.com

INVESTOR ALERT: Investigation of Replimune Group, Inc. (REPL) Announced by Holzer & Holzer, LLC

July 22 at 1:17 PM | globenewswire.com

Replimune Group (NASDAQ:REPL) Earns Neutral Rating from JPMorgan Chase & Co.

July 22 at 12:44 PM | marketbeat.com

Replimune Group (NASDAQ:REPL) Downgraded to Neutral Rating by Piper Sandler

July 22 at 11:25 AM | marketbeat.com

Replimune Group (NASDAQ:REPL) Downgraded to "Neutral" Rating by Wedbush

July 22 at 11:25 AM | marketbeat.com

BREAKING: Replimune Group, Inc. Shares Drop 70%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

July 22 at 11:03 AM | globenewswire.com

Replimune Group (NASDAQ:REPL) Sees Large Volume Increase - Here's Why

July 21 at 1:47 PM | marketbeat.com

Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of "Buy" from Analysts

July 20 at 4:54 AM | marketbeat.com

Replimune Group (NASDAQ:REPL) Stock Price Down 5.2% - Here's What Happened

July 19, 2025 | marketbeat.com

Replimune Group (NASDAQ:REPL) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

July 18, 2025 | americanbankingnews.com

Investors Purchase High Volume of Call Options on Replimune Group (NASDAQ:REPL)

July 17, 2025 | americanbankingnews.com

Replimune Group (NASDAQ:REPL) Shares Gap Up Following Analyst Upgrade

July 17, 2025 | americanbankingnews.com

Replimune Group (NASDAQ:REPL) Shares Gap Up on Analyst Upgrade

July 16, 2025 | marketbeat.com

Replimune Group (NASDAQ:REPL) Price Target Raised to $19.00 at JPMorgan Chase & Co.

July 16, 2025 | marketbeat.com

Replimune Group (NASDAQ:REPL) Trading Up 5.7% - Time to Buy?

July 15, 2025 | marketbeat.com

Replimune Group Target of Unusually High Options Trading (NASDAQ:REPL)

July 15, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
Payment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?
By Gabriel Osorio-Mazilli | June 23, 2025
View Payment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?

REPL, PTGX, MLTX, and IMVT Company Descriptions

Immunovant NASDAQ:IMVT

$17.94 +0.24 (+1.36%)

Closing price 07/22/2025 04:00 PM Eastern

Extended Trading

$18.05 +0.11 (+0.62%)

As of 07/22/2025 07:58 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

MoonLake Immunotherapeutics NASDAQ:MLTX

$53.57 0.00 (0.00%)

Closing price 07/22/2025 04:00 PM Eastern

Extended Trading

$53.60 +0.03 (+0.06%)

As of 07/22/2025 07:47 PM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Protagonist Therapeutics NASDAQ:PTGX

$54.99 -0.23 (-0.42%)

Closing price 07/22/2025 04:00 PM Eastern

Extended Trading

$52.33 -2.66 (-4.84%)

As of 07/22/2025 07:44 PM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Replimune Group NASDAQ:REPL

$2.81 -9.51 (-77.19%)

Closing price 07/22/2025 04:00 PM Eastern

Extended Trading

$2.84 +0.02 (+0.89%)

As of 07/22/2025 08:00 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time